Trends & Forecasts

What happened at ISCT 2022’s return to in-person conferencing – and what can a new film release do for advanced therapy?

The International Society for Cell & Gene Therapy convened in person for the first time in two years. We spoke to an attendee for an insight

In our third C+G Champions installment, we ask industry leaders in the cell and gene field about accessibility for the many

The Medicine Maker and NIBRT present the Biopharma Trends Leaders’ Report 2022.

An inside view of the pharmaceutical industry in China. Where has it been, where does it stand, and where is it going?

It’s been a busy time for infectious disease vaccine news in Europe.

Our animated chart illustrates Pfizer’s changing fortunes – and the significant contribution its COVID-19 efforts have made to revenues.

Ukrainian drug discovery has been disrupted by war. We spoke to leaders of its largest player about the domestic industry’s past, present, and future.

The war in Ukraine has massively impacted clinical trials. We spoke to one man tracking the disruption.

One decade behind the EU, biosimilars are arriving in the US. What can we expect? Jeff Baldetti from Cardinal Health has a few ideas.